In the VALIANT study [17], addition of ARB valsartan to ACE inhibitor resulted in similar degree of post-MI left ventricular (LV) remodeling compared to either drug alone, although in the Val-HeFT study [18], LV remodeling in heart failure was more favorable in the combination therapy group. The gene discussed is ACE; the disease is heart failure.